Zelniker TA, Bonaca MP, Furtado R, et al. - Researchers determined if a reduction in the risk of atrial fibrillation (AF)/atrial flutter (AFL) may be brought about by SGLT2i. Among 17,160 patients with T2D and either multiple risk factors for (n = 10,186) or known atherosclerotic cardiovascular disease (ASCVD, n = 6,974), an analysis of the efficacy as well as safety of the SGLT2i dapagliflozin vs placebo was performed in the DECLARE-TIMI 58. Experts used Cox and negative binomial models to assess the influence of dapagliflozin on the first and total number of AF/AFL events among patients with (n = 1,116) and without prevalent AF/AFL, respectively. Findings revealed a reduced incidence of reported episodes of AF/AFL adverse events in relation to treatment with dapagliflozin among high-risk patients with T2D. This effect was found to be consistent irrespective of the patients' previous history of AF, ASCVD, or heart failure.